Results 71 to 80 of about 11,159 (187)
Review of the pharmacology and clinical studies of micafungin
, 2009 Alison M Bormann1, Vicki A Morrison21Division of Infectious Diseases, University of Minnesota, Minneapolis, MN, USA; 2Division of Hematology/Oncology and Infectious Disease, Minneapolis Veterans Affairs Medical Center, Minneapolis, MN, USAAbstract ...
Vicki A Morrison, Alison M Bormann
core
Frontiers in PediatricsUrinary tract infections (UTIs) associated with indwelling urinary catheterization (IUC) in premature newborns (PNBs) pose a significant challenge in neonatal intensive care units (NICUs) due to the vulnerability of this population to infections and the ...
Carlos Javier Parramon-Teixido +6 more
doaj +1 more source
Journal of Fungi, 2019 This paper reviews recent advances in three selected areas of pediatric invasive candidiasis: epidemiology, diagnosis, and treatment. Although the epidemiological trends of pediatric invasive candidiasis illustrate a declining incidence, this infection ...
Thomas J. Walsh +4 more
doaj +1 more source
Micafungin use in a UK tertiary referral hospital
, 2018 Objectives: Here we sought to describe the real-life usage of micafungin in a UK tertiary referral hospital. Methods: A prospective, non-interventional, observational surveillance study was performed in a large teaching hospital do we need ‘in a large ...
Aliyu, Sani H. +5 more
core +1 more source
Results of the use of micafungin in newborns
, 2019 Invasive candidiasis is a common and serious infection in premature newborns. Preventing and treating fungal infections is very important to improve the prognosis of premature infants.
core +2 more sources
Medication Use Evaluation - Micafungin
, 2018 Echinocandins are becoming increasingly important in the management of Candida infections due to the emergence of azole-resistant Candida species. The purpose of this medication use evaluation (MUE) was to assess the patterns of micafungin use throughout
Briggs, Alyse +3 more
core +1 more source
The activity of micafungin against clinical isolates of non-albicans Candida spp.
Current Issues in Pharmacy and Medical Sciences, 2015 Infections caused by non-albicans Candida spp. are an important medical problem in people from risk groups, e.g. hematooncological patients. The aim of this paper was to analyse the in vitro activity of micafungin against 30 clinical isolates of non ...
Biernasiuk Anna +3 more
doaj +1 more source
, 2014 To explore the pharmacokinetics (PK) and pharmacodynamics (PD) of micafungin in patients undergoing continuous venovenous haemofiltration (CVVH)
Luque, Sonia +15 more
core +1 more source
, 2012 Invasive fungal infections have emerged as a major cause of increased morbidity and mortality among severely immunosuppressed patients with haematological malignancy.
Kontoyiannis, D.P. +2 more
core +1 more source
Micafungin Concentrations in the Plasma and Burn Eschar of Severely Burned Patients
, 2012 Micafungin concentrations in plasma and burn eschar after daily intravenous infusion (1 h) of micafungin (200 to 300 mg) were investigated for six patients with severe burns. Micafungin treatment was initiated more than 72 h after the burn injuries.
Yotaro Shinozawa +10 more
core +1 more source